American Optometric Association Clinical Report Examines GLP-1 Receptor Agonists and Ocular Risk
Wednesday, April 22 2026 | 08 h 37 min | Optik Magazine, Vision Science
At A Glance
- New clinical report issued by the American Optometric Association
- Reviews ocular risks linked to GLP-1 receptor agonists
- Medications commonly used for diabetes and weight management
- Highlights possible associations with diabetic retinopathy progression and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Summary
The American Optometric Association has released an evidence-based clinical report reviewing ocular considerations associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide and tirzepatide. While these medications play an important role in managing systemic metabolic disease, emerging observational data suggest potential associations with diabetic retinopathy progression and rare optic nerve events.
The report emphasizes careful baseline assessment and ongoing ocular monitoring for patients prescribed these therapies.
Practice Considerations
Optometrists should update medication histories routinely and maintain heightened vigilance when managing patients on GLP-1RAs, particularly those with pre-existing retinal disease. Clear interprofessional communication with primary care providers and endocrinologists remains essential to coordinated care.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e- newsletters!
